Vaxcyte, Inc. (PCVX)
Nasdaq: PCVX · Biological Products, (No Diagnostic Substances) · San Carlos, CA · filing with the SEC since 2015
Who owns Vaxcyte, Inc.
As filed with the SECHolders of 5% or more
6
Fmr LLC holds 14.4% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 6, 2026 says.
Directors and officers
16
report now, of 26 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 11.4% in May 6, 2026
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G/A · filed Aug 11, 2026 · Common Stock · 0.1% in Aug 7, 2026
RA Capital Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value per share · 9.9% in May 15, 2025
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Feb 17, 2026 · COMMON STOCK · 6.4% in Nov 14, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What PCVX reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 27, 2024.
Insider tradesForm 4
58sales
0purchases
49sales on a scheduled plan
5people selling
$12.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 38 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Pickering Grant | CHIEF EXECUTIVE OFFICER | 19 | $3.6M | 19 | 0 | $0 |
| Wassil Jim | EVP, Chief Scientific Ofc, COO | 23 | $3.3M | 17 | 0 | $0 |
| Cowan Elvia | SVP, Finance & CAO | 9 | $2.8M | 7 | 0 | $0 |
| Guggenhime Andrew | PRESIDENT AND CFO | 5 | $1.6M | 5 | 0 | $0 |
| Dhaliwal Harpreet S. | Chief Technical Ops Officer | 2 | $1.4M | 1 | 0 | $0 |